Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: Economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study

Clinical Therapeutics

Volumn 30, Issue PART 2, 2008, Pages 2204-2216

  Mullins, C Daniel ^a   Rattinger, Gail B ^a   Kuznik, Andreas ^b   Koren, Michael J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b PFIZER INC   (United States)

^c Jacksonville Center for Clinical Research   (United States)

Author keywords

cholesterollowering drugs; coronary heart disease; cost effectiveness; statins

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG MARKETING; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; RISK REDUCTION;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; HEPTANOIC ACIDS; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MODELS, ECONOMIC; MYOCARDIAL REVASCULARIZATION; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 61649095701     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.007     Document Type: Article

References (69)

1. Mullins C.D., Wang J., Palumbo F.B., and Stuart B. The impact of pipeline drugs on drug spending growth. Health Aff (Millwood) 20 (2001) 210-215
2. Morgan S.G. Quantifying components of drug expenditure inflation: The British Columbia seniors' drug benefit plan. Health Serv Res 37 (2002) 1243-1266
3. Banthin J.S., and Miller G.E. Trends in prescription drug expenditures by Medicaid enrollees. Med Care 44 Suppl 5 (2006) 127-135
4. Heffler S., Smith S., Keehan S., et al. US health spending projections for 2004-2014 (2005), Health Aff, Millwood Suppl(Web Exclusives):W5-74-W5-85
5. Hoffman J.M., Shah N.D., Vermeulen L.C., et al. Projecting future drug expenditures-2008. Am J Health Syst Pharm 65 (2008) 234-253
6. Huh S., Rice T., and Ettner S.L. Prescription drug coverage and effects on drug expenditures among elderly Medicare beneficiaries. Health Serv Res 43 (2008) 810-832
7. Lichtenberg F.R., and Sun S.X. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood) 26 (2007) 1735-1744
8. Zuvekas S.H., and Cohen J.W. Prescription drugs and the changing concentration of health care expenditures. Health Aff (Millwood) 26 (2007) 249-257
9. Joyce G.F., Escarce J.J., Solomon M.D., and Goldman D.P. Employer drug benefit plans and spending on prescription drugs. [published correction appears in JAMA. 2002;288:2409]. JAMA 288 (2002) 1733-1739
10. Motheral B., and Sheth J. Financial consequences of drug benefit plans. JAMA 289 (2003) 423-424 author reply 424
11. Motheral B.R., Henderson R., and Cox E.R. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care 10 (2004) 457-464
12. Fairman K.A., Motheral B.R., and Henderson R.R. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 25 (2003) 3147-3161 discussion 3144-3146
13. Klepser D.G., Huether J.R., Handke L.J., and Williams C.E. Effect on drug utilization and expenditures of a cost share change from copayment to coinsurance. J Manag Care Pharm 13 (2007) 765-777
14. Miller D.P., Furberg C.D., Small R.H., et al. Controlling prescription drug expenditures: A report of success. Am J Manag Care 13 (2007) 473-480
15. Reiffel J.A. Formulation substitution: A frequently overlooked variable in cardiovascular drug management. Prog Cardiovasc Dis 47 (2004) 3-10
16. Andermann F., Duh M.S., Gosselin A., and Paradis P.E. Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes. Epilepsia 48 (2007) 464-469
17. Haas J.S., Phillips K.A., Gerstenberger E.P., and Seger A.C. Potential savings from substituting generic drugs for brandname drugs: Medical expenditure panel survey, 1997-2000. [published comment and reply appear in Ann Intern Med. 2005;143:844-845]. Ann Intern Med 142 (2005) 891-897
18. Schulman K.A., Rubenstein L.E., Abernethy D.R., et al. The effect of pharmaceutical benefits managers: Is it being evaluated?. Ann Intern Med 124 (1996) 906-913
19. Murphy J.E. Generic substitution and optimal patient care. Arch Intern Med 159 (1999) 429-433
20. Mager D.E., and Cox E.R. Relationship between generic and preferredbrand prescription copayment dif ferentials and generic fill rate. Am J Manag Care 13 (2007) 347-352
21. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
22. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
23. Morrison A., and Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 9 (2003) 544-551
24. Thorpe K.E. Factors accounting for the rise in health-care spending in the United States: The role of rising disease prevalence and treatment intensity. Public Health 120 (2006) 1002-1007
25. Thorpe K.E., and Howard D.H. The rise in spending among Medicare beneficiaries: The role of chronic disease prevalence and changes in treatment intensity. Health Aff (Millwood) 25 (2006) w378-w388
26. Cannon C.P., Braunwald E., McCabe C.H., et al., for the Pravastatin or Atorvastatin Evaluation and infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006; 354:778]. N Engl J Med 350 (2004) 1495-1504
27. Grundy S.M., Cleeman J.I., Merz C.N., et al., for the Coordinating Committee of the National Cholesterol Education Program. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24 (2004) 1329-1330
28. Grundy S.M., Cleeman J.I., Merz C.N., et al., for the National Heart, Lung, and Blood Institute; the American College of Cardiology Foundation; and the American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763]. Circulation 110 (2004) 227-239
29. Pravachol [package insert] (2007), Bristol-Myers Squibb Company, Princeton, NJ
30. Mevacor [package insert] (2008), Merck, Whitehouse Station, NJ
31. Zocor [package insert] (2008), Merck, Whitehouse Station, NJ
32. Gumbs P.D., Verschuren W.M., Souverein P.C., et al. Society already achieves economic benefits from generic substitution but fails to do the same fortherapeutic substitution. Br J Clin Pharmacol 64 (2007) 680-685
33. Straka R.J., Mamdani M., Damen J., et al. Economic impacts attributable to the early clinical benefit of atorvastatin therapy-a US managed care perspective. Curr Med Res Opin 23 (2007) 1517-1529
34. Meissner B., Dickson M., Shinogle J., et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. [published correction appears in J Manag Care Pharm. 2006;12:490]. J Manag Care Pharm 12 (2006) 331-340
35. Reuters. Examine the Lipitor market analysis and forecast report, 20072012, 2017 and 2023. http://www.reuters.com/article/pressRelease/idUS244565+25-Jun-2008+MW200 80625 Accessed November 11, 2008.
36. Schaefer E.J., McNamara J.R., Tayler T., et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93 (2004) 3139
37. Olsson A.G., Eriksson M., Johnson O., et al., for the 3T Study Investigators. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The Treat-to-Target (3T) Study. Clin Ther 25 (2003) 119-138
38. Plosker G.L., and Lyseng-Williamson K.A. Atorvastatin: A pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. Pharmaco Economics 25 (2007) 1031-1053
39. Lindgren P., Graff J., Olsson A.G., et al., for the IDEAL Trial Investigators. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur HeartJ 28 (2007) 1448-1453
40. Koren M.J., Hunninghake D.B., and for the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE study. J Am Coll Cardiol 44 (2004) 1772-1779
41. 2007 Drug Topics Red Book (2007), Thomson Medical Economics, Montvale, NJ
42. Thompson D, RubinJL, Nyambose J, et al. A flexible tool to estimate medical-care costs for study events in cardiovascular endpoint trials. Presented at: 13th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 2008; Toronto, Canada.
43. Bureau of Labor Statistics. Consumer price index. http://www.bls.gov/cpi Accessed June 11, 2008.
44. Sever P.S., Dahlöf B., Poulter N.R., et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
45. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
46. Pedersen T.R., Faergeman O., Kastelein J.J., et al., for the Incremental Decrease in End Points Through Ag gressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial [published correction appears in JAMA. 2005; 294:3092]. JAMA 294 (2005) 2437-2445
47. La Rosa J.C., Grundy S.M., Waters D.D., et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
48. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Choles terol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronaryheart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
49. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285 (2001) 1711-1718
50. Cannon C.P., Steinberg B.A., Murphy S.A., et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
51. Davies A., Hutton J., O'Donnell J., and Kingslake S. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHID in the UK. Br J Cardiol 13 (2006) 196-202
52. Lindgren P., Buxton M., Kahan T., et al., for the ASCOT Investigators. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: An economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil 12 (2005) 29-36
53. Russell M.W., Huse D.M., Miller J.D., et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 8 (2001) 9-16
54. Chan P.S., Nallamothu B.K., Gurm H.S., et al. Incremental benefit and cost-effectiveness of high-dose stat in therapy in high-risk patients with coronary artery disease. Circulation 115 (2007) 2398-2409
55. Elliott W.J., and Weir D.R. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm 56 (1999) 1726-1732
56. Robinson J.G. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am J Cardiol 101 (2008) 1009-1015
57. Arca M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 67 Suppl 1 (2007) 43-54
58. Arca M., and Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs 67 Suppl 1 (2007) 29-42
59. Bybee K.A., Lee J.H., and O'Keefe J.H. Cumulative clinical trial data on atorvastatin for reducing cardiovas cular events: The clinical impact of atorvastatin. Curr Med Res Opin 24 (2008) 1217-1229
60. Gresser U., and Gathof B.S. Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke comparison of the clinical benefit of statin on the basis of randomized controlled endpoint studies. Eur J Med Res 9 (2004) 1-17
61. Ramsey S.D., Clarke L.D., Roberts C.S., et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmaco Economics 26 (2008) 329-339
62. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) [published correction appears in Am J Cardiol. 1998;82:128]. Am J Cardiol 81 (1998) 582-587
63. Cox E.R., Kulkarni A., and Henderson R. Impact of patient and plan design factors on switching to preferred statin therapy. Ann Pharmacother 41 (2007) 1946-1953
64. Usher-Smith J., Ramsbottom T., Pearmain H., and Kirby M. Evaluation of the clinical outcomes of switching pa tients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 Years on. Int J Clin Pract 62 (2008) 480-484
65. Usher-Smith J.A., Ramsbottom T., Pearmain H., and Kirby M. Evaluation of the cost savings and clinical out comes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract 61 (2007) 15-23
66. Thiebaud P., Patel B.V., Nichol M.B., and Berenbeim D.M. The effect of switching on compliance and persistence: The case of statin treatment. Am J Manag Care 11 (2005) 670-674
67. Hess G., Sanders K.N., Hill J., and Liu L.Z. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin [published correction appears in Am J Manag Care. 2007;13: 432]. Am J Manag Care 13 Suppl 3 (2007) 580-585
68. Molden E., Andersson K.S., and Jacobsen D. Interactions between statins and macrolide antibiotics [in Norwegian]. Tidsskr Nor Laegeforen 127 (2007) 1660-1661
69. Mandelblatt J.S., Fryback D.G., Weinstein M.C., et al. Assessing the costeffectiveness of health interventions. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY 135-175